DRD1在神经系统疾病和功能中的研究进展

李瑾瑜; 冯良升; 高扬; 李钰; 吴帮旭; 邹英鹰

doi:10.12259/j.issn.2095-610X.S20240501

DRD1在神经系统疾病和功能中的研究进展

doi: 10.12259/j.issn.2095-610X.S20240501

1.
昆明医科大学第一临床医学院，云南昆明　650032
2.
昆明医科大学基础医学院，云南昆明　650500

基金项目: 国家自然科学基金资助项目（32060184）；昆明医科大学大学生创新创业训练基金资助项目（2023CXD267）

详细信息

作者简介:
李瑾瑜（2004～），女，云南昆明人，昆明医科大学在读本科生

通讯作者:
邹英鹰，E-mail：zouyingyingzyy@126.com

中图分类号: R741.02
计量
- 文章访问数: 1833
- HTML全文浏览量: 1141
- PDF下载量: 64
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-11
- 网络出版日期: 2024-04-29
- 刊出日期: 2024-05-31

Research Progress of DRD1 in Neurological Disorders and Functions

1.
The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032
2.
School of Basic Medicine of Kunming Medical University，Kunming Yunnan 650500，China

More Information

Corresponding author: 邹英鹰，教授，博士生/硕士生导师, 云南省“兴滇英才支持计划” 教学名师、享受云南省特殊津贴专家、云南省中青年学术和技术带头人、云南省卓越青年教师，从事病理学教学科研工作24 a。现任昆明医科大学基础医学院副院长。长期致力于糖尿病性中枢神经损伤及保护的研究，并取得一定的相关成果。包括发现糖尿病长期病变可导致视网膜、海马、嗅球、小脑等多部位损伤及其功能障碍，提出这些部位损伤的部分分子机制，并积极开展云南特色药物天麻素修复糖尿病性中枢神经系统损伤的机制研究。先后主持各级科研项目8项，其中国家自然科学基金项目4项、省级重点项目1项等。目前以通讯、第一作者发表高水平外文论文15篇。此外，主持各级病理学课程及教学改革项目10项，其中包括国家级一流本科课程2门、省部级教学项目3项、校级质量工程项目5项等。担任第二届中国研究型医院学会超微与分子病理学专业委员会委员、中华医学会病理学分会第十二届委员会病理学教学工作委员会委员、云南省医师协会病理医师分会第三届委员会常委等。

摘要

摘要: 多巴胺D1受体（dopamine D1 receptor ，DRD1）是目前已知神经系统表达最广泛的多巴胺受体亚型。DRD1能通过多种信号通路发挥运动、情感、认知、学习记忆以及神经内分泌等功能。这些功能可能与帕金森综合征、精神分裂症、抑郁症等精神疾病以及免疫有关。而DRD1的表达变化通常提示了神经系统功能的改变。因此DRD1可以作为神经系统疾病和功能变化的潜在指标和神经系统疾病治疗的潜在靶点。综述DRD1在神经系统中的分布和功能，重点强调DRD1与神经系统相关的信号通路。
- 多巴胺受体 /
- 神经系统 /
- DRD1 /
- 多巴胺
Abstract: Dopamine D1 receptor （DRD1） is currently known as the dopamine receptor subtype with the most widespread expression in the nervous system. DRD1 plays a role in various signaling pathways to perform many functions such as movement, emotion, cognition, learning and memory, as well as neuroendocrine activities. These functions may be associated with conditions like Parkinson's syndrome, schizophrenia, depression, and immune responses. Changes in the expression of DRD1 often indicate alterations in neurological functions. Therefore, DRD1 has the potential to serve as an indicator of neurological disorders and functional changes, as well as a potential target for the treatment of neurological diseases. This article reviews the distribution and functions of DRD1 in the nervous system, with a particular emphasis on DRD1's involvement in signaling pathways related to the nervous system.
- Dopamine receptor /
- Nervous system /
- DRD1 /
- DA

HTML全文

参考文献(61)

[1]	Sioka C,Fotopoulos A,Kyritsis A P. Recent advances in PET imaging forevaluation of Parkinson's disease[J]. Eur J Nucl Med Mol Imaging,2010,37(8):1594-1603. doi: 10.1007/s00259-009-1357-9
[2]	Wei X,Ma T,Cheng Y,et al. Dopamine D1 or D2 receptor-expressing neurons in the central nervous system[J]. Addict Biol,2018,23(2):569-584. doi: 10.1111/adb.12512
[3]	Zang X,Cheng Z Y,Sun Y,et al. The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ1-42-induced cognitive impairment[J]. Prog Neuropsychopharmacol Biol Psychiatry,2018,2(81):250-261.
[4]	Kim M,Custodio R J,Lee H J,et al. Per2 Expression regulates the spatial working memory of mice through DRD1-PKA-CREB signaling[J]. Mol Neurobiol,2022,59(7):4292-4303. doi: 10.1007/s12035-022-02845-z
[5]	C Missale, S R Nash, S W Robinson, et al. Dopamine receptors: From structure to function[J]. Physiol Rev,1998,78(1):189-225.
[6]	Trzaskowski B,Latek D,Yuan S,et al. Action of molecular switches in GPCRs-theoretical and experimental studies[J]. Curr Med Chem,2012,19(8):1090-1109.
[7]	曹国祥. 多巴胺受体显像剂的研究概况[J]. 国外医学(放射医学核医学分册),1999,23(2):65-67
[8]	Wen X S,Chen X M,Rong F,et al. The regulation of SKF38393 on the dopamine and D1 receptor expression in hippocampus during chronic REM sleep restriction[J]. CNS Neurosci Ther,2013,19(9):730-733. doi: 10.1111/cns.12140
[9]	乔晋萍,乔洪文,武仙英,等. 多巴胺神经系统显像分子探针研究[J]. 生命的化学,2014,34(2):154-165.
[10]	Gouveri E,Katotomichelakis M,Gouveris H,et al. Olfactory dysfunction in type 2 diabetes mellitus: an additional manifestation of microvascular disease?[J]Angiology,2014,65(10): 869-876.
[11]	李瑞,范运龙,刘海鹰,等. 多巴胺D1受体在小鼠大脑皮层的空间分布研究[J]. 神经解剖学杂志,2019,35(3):229-235.
[12]	De Bundel D,Femen í a T,DuPont C M,et al. Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine[J]. Int J Neuropsychopharmacol,2013,16(9):2041-51. doi: 10.1017/S1461145713000370
[13]	Liu A,Ding S. Anti-inflammatory Effects of Dopamine in lipopolysaccharide (LPS)-stimulated RAW264.7 cells via inhibiting NLRP3 inflammasome activation[J]. Ann Clin Lab Sci,2019,49(3):353-360.
[14]	Seamans J K,Yang C R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex[J]. Prog Neurobiol,2004,74(1):1-57. doi: 10.1016/j.pneurobio.2004.05.006
[15]	张国炳, 陈峻严, 孙文栋,等. 多巴胺D1受体基因(-48A/G)多态性与额叶挫裂伤后认知障碍相关性[J]. 中华实验外科杂志,2016,33(4):993-996.
[16]	J M Beaulieu,S Espinoza,R R Gainetdinov. Dopamine receptors - IUPHAR review 13[J]. Britisch Journal of Pharmacology,2015,172(1): 1-23.
[17]	王功伍,蔡景霞. 海马-前额叶神经回路与工作记忆[J]. 动物学研究,2010,31(1):50-56.
[18]	Tsang J,Fullard J F,Giakoumaki S G,et al. The relationship between dopamine receptor D1 and cognitive performance[J]. NPJ Schizophr,2015,4(1):14002.
[19]	El-Ghundi M,Fletcher P J,Drago J,et al. Spatiallearning deficit in dopamine D(1) receptor knockout mice[J]. Eur J Pharmacol,1999,383(2):95-106. doi: 10.1016/S0014-2999(99)00573-7
[20]	Tractenberg S G,Orso R,Creutzberg K C,et al. Vulnerable and resilient cognitive performance related to early life stress: The potential mediating role of dopaminergic receptors in the medial prefrontal cortex of adult mice[J]. Int J Dev Neurosci,2020,80(1):13-27. doi: 10.1002/jdn.10004
[21]	胡一文,王高华,顾剑. 精神分裂症患者多巴胺D1受体基因-48A/G多态性与认知功能的关系[J]. 中国神经精神疾病杂志,2006,32(6):523-526. doi: 10.3969/j.issn.1002-0152.2006.06.009
[22]	李凡,舒斯云,包新民. 多巴胺受体的结构和功能[J]. 中国神经科学杂志,2003,19(6):405-410.
[23]	Smith, Y Raju, D V Pare, et al. The thalamostriatal system: A highly specific network of the basal ganglia circuitry[J]. Trends Neurosci,2004,27(9):520-527.
[24]	Darmopil S, Mart í n A B, De Diego I R, et al. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation[J]. Biol Psychiatry,2009,66(6):603-613.
[25]	Reid K M,Steel D,Nair S,et al. Loss-of-function variants in DRD1 in infantile Parkinsonism-dystonia[J]. Cells,2023,12(7):1046.
[26]	Toma C,Herv á s A,Balmaña N,et al. Neurotransmitter systems and neurotrophic factors in autism: Association study of 37 genes suggests involvement of DDC[J]. World J Biol Psychiatry,2013,14(7):516-527. doi: 10.3109/15622975.2011.602719
[27]	Cartier E,Hamilton P J,Belovich A N,et al. Rare autism-associated variants implicate syntaxin 1 (STX1 R26Q) phosphorylation and the dopamine transporter (hDAT R51W) in dopamine neurotransmission and behaviors[J]. EBio Medicine,2015,2(2):135-146. doi: 10.1016/j.ebiom.2015.01.007
[28]	Corrales E,Navarro A,Cuenca P,et al. Candidate gene study reveals DRD1 and DRD2 as putative interacting risk factors for youth depression[J]. Psychiatry Res,2016,244(11):71-77.
[29]	Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia[J]. Life Science,1999,65(22):2269-2287.
[30]	Odum A L. Delay discounting: I'm a k,you're a k[J]. J Exp Anal Behav,2011,96(3):427-439. doi: 10.1901/jeab.2011.96-423
[31]	Bickel W K,Jarmolowicz D P,Mueller E T,et al. Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other disease-related vulnerabilities: Emerging evidence[J]. Pharmacol Ther,2012,134(3):287-297. doi: 10.1016/j.pharmthera.2012.02.004
[32]	Moses T E H,Burmeister M,Greenwald M K. Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation[J]. Addict Biol,2020,25(3):e12777. doi: 10.1111/adb.12777
[33]	Ashe M L,Newman M G,Wilson S J. Delay discounting and the use of mindful attention versus distraction in the treatment of drug addiction: A conceptual review[J]. J Exp Anal Behav,2015,103(1):234-248. doi: 10.1002/jeab.122
[34]	Lee W,Ray R,Bergen A W,et al,Thomas P. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers[J]. Pharmacogenet Genomics,2012,22(7):551-4. doi: 10.1097/FPC.0b013e3283539062
[35]	Yan. Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome[J]. Cell,2015,160(1-2):62-73. doi: 10.1016/j.cell.2014.11.047
[36]	Cosentino M,Fietta A M,Ferrari M,et al. Human CD4⁺CD25⁺ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholaminessubserving an autocrine/paracrine inhibitory functional loop[J]. Blood,2007,109(2):632-642. doi: 10.1182/blood-2006-01-028423
[37]	Ferrari M,Cosentino M,Marino F,et al. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNAexpression and catecholamine production in human lymphocytes[J]. Biochem Pharmacol,2004,67(5):865-873. doi: 10.1016/j.bcp.2003.10.004
[38]	Tsunoda M. Role of catecholamine metabolism in blood pressure regulation using chemiluminescence reactiondetection[J]. Yakugaku Zasshi,2008,128(11):1589-1594 . doi: 10.1248/yakushi.128.1589
[39]	M ravec B. Role of catecholamine-induced activation of vagal afferent pathways in regulation of sympathoadrenal system activity: Negative feedback loop of stress response[J]. Endocr Regul,2011,45(1):37-41 .
[40]	Nakano K,Higashi T,Takagi R,et al,Matsushita S. Dopaminereleased by dendritic cells polarizes Th2 differentiation[J]. Int Immunol,2009,21(6):645-654. doi: 10.1093/intimm/dxp033
[41]	Zanassi P,Paolillo M,Montecucco A,et al. Pharmacological and molecular evidence for dopamine D(1) receptor expression bystriatal astrocytes in culture[J]. J Neurosci Res,1999,58(4):544-552. doi: 10.1002/(SICI)1097-4547(19991115)58:4<544::AID-JNR7>3.0.CO;2-9
[42]	Zhang X,Zhou Z,Wang D,et al. Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2expression in astrocytes via IP3-dependent Ca2+ signaling[J]. J Neurosci,2009,29(24):7766-7775 . doi: 10.1523/JNEUROSCI.0389-09.2009
[43]	Beaulieu J M,Gainetdinov R R. The physiology,signaling,and pharmacology of dopamine receptors[J]. Pharmacological Reviews,2011,63(1):182-217. doi: 10.1124/pr.110.002642
[44]	Ng J, Barral S, Waddington S N, et al. Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the clinical phenotype and precision medicine approaches[J]. Cells, 2023, 12(13):1737. Ng J, Barral S, Waddington S N, et al. Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the clinical phenotype and precision medicine approaches[J]. Cells, 2023,12(13):1737.
[45]	张超洁,商亚珍. CREB与阿尔茨海默病[J]. 承德医学院学报,2023,40(3):237-241.
[46]	Brami-Cherrier K,Valjent E,Garcia M,et al. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: A new route to cAMP response element-binding protein phosphorylation[J]. J Neurosci,2002,22(20):8911-8921. doi: 10.1523/JNEUROSCI.22-20-08911.2002
[47]	Monsma F J,Jr.,Mahan L C,et al. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation[J]. Proc Natl Acad Sci USA,1990,87(17):6723-6727. doi: 10.1073/pnas.87.17.6723
[48]	Cosentino M,Kustrimovic N,Ferrari M,et al. cAMP levels in lymphocytes and CD4+ regulatory T-cell functions are affected by dopamine receptor gene polymorphisms[J]. Immunology,2018,153(3):337-341. doi: 10.1111/imm.12843
[49]	D’ SaC ,Duman R S . Antidepressants and neuroplasticity[J]. Bipolar Disord,2002,4(3): 183-194.
[50]	李云峰,杨明,赵毅民,等. 巴戟天寡糖对皮质酮损伤的PC12细胞的保护作用[J]. 中国中药杂志,2000,25(9):39-42.
[51]	李云峰,罗质璞. 丁螺环酮对皮质酮所致PC12细胞损伤的保护作用[J]. 中国药理学与毒理学杂志,2001,15(5):333-336.
[52]	Possemato E, La Barbera L, Nobili A, et al. The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases[J]. Ageing Res Rev,2023,87(1):101907.
[53]	Yang C,Kazanietz M G. Divergence and complexities in DAG signaling: Looking beyond PKC[J]. Trends Pharmacol Sci,2003,24(11):602-608. doi: 10.1016/j.tips.2003.09.003
[54]	Felder C C,Jose P A,Axelrod J. The dopamine-1 agonist,SKF 82526,stimulates phospholipase-C activity independent of adenylate cyclase[J]. J Pharmacol Exp Ther,1989,248(1):171-175.
[55]	Berridge M J. Inositol trisphosphate and calcium signalling mechanisms[J]. Biochim Biophys Acta,2009,1793(6):933-940. doi: 10.1016/j.bbamcr.2008.10.005
[56]	Qin D,Liu P,Chen H,et al. Salicylate-induced ototoxicity of spiral ganglion neurons: Ca2⁺/CaMKII-mediated interaction between NMDA receptor and GABAA receptor[J]. Neurotox Res,2019,35(4):838-847. doi: 10.1007/s12640-019-0006-8
[57]	Zeng C,Villar V A,Yu P,et al. Reactive oxygen species and dopamine receptor function in essential hypertension[J]. Clin Exp Hypertens,2009,31(2):156-178. doi: 10.1080/10641960802621283
[58]	Kansra V,Chen C J,Lokhandwala M F. Dopamine fails to stimulate protein kinase C activity in renal proximal tubules of spontaneously hypertensive rats[J]. Clin Exp Hypertens,1995,17(5):837-845. doi: 10.3109/10641969509033638
[59]	Kim B,Yun J,Park B. Methamphetamine-induced neuronal damage: Neurotoxicity and neuroinflammation[J]. Biomol Ther,2020,28(5):381-388.
[60]	Premoli M, Aria F, Bonini S A, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment[J]. Life Sci,2019,224(1):120-127.
[61]	Vitale R M, Iannotti F A, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: Molecular mechanisms and targets[J]. International Journal of Molecular Sciences,2021,22(9):4876.

计量

文章访问数: 1833
HTML全文浏览量: 1141
PDF下载量: 64
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

DRD1在神经系统疾病和功能中的研究进展

doi: 10.12259/j.issn.2095-610X.S20240501

作者简介:
李瑾瑜（2004～），女，云南昆明人，昆明医科大学在读本科生

通讯作者:
邹英鹰，E-mail：zouyingyingzyy@126.com

计量

Research Progress of DRD1 in Neurological Disorders and Functions

计量

目录

[1]	门欣怡, 赵静, 申永椿, 季辉, 王秀霞. 外周血免疫球蛋白、血沉、同型半胱氨酸与儿童中枢神经系统血管炎病情程度的关系及对预后的影响, 昆明医科大学学报.
[2]	张盛庆宇, 舒逍, 吴锡南, 李志强, 武慧欣, 张媛, 蒋玉融, 杨思佳, 木云珍. 1 800 MHz射频电磁场暴露对大鼠海马GFAP、NCAM和GABA受体表达的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210939
[3]	金锦花, 李科岩, 张玲, 王玉慧, 邓晓明. 成纤维细胞生长因子受体FGFR1真核表达质粒的构建及其在HEK293T细胞的表达, 昆明医科大学学报.
[4]	谢巍, 赵川, 王容, 王文平, 涂宏. 慢性乙型肝炎患者外周血T淋巴细胞程序性死亡受体1表达与HBV-DNA水平的相关性, 昆明医科大学学报.
[5]	王一航, 洪仕君, 钟磊磊, 解润芳, 彭艳霞, 李利华. DA、5-HT及MAO在甲基苯丙胺和氯胺酮联合滥用依赖大鼠CPP效应中的表达量变化, 昆明医科大学学报.
[6]	陈志彬, 莫艳萍, 杨钰, 陈灿昆, 杨靖宜, 万瑞雪, 范志祥, 龙莉. 趋化因子受体CX3CR1基因T280M多态性在云南彝族人群中的分布, 昆明医科大学学报.
[7]	张帆. Toll样受体-2和血红素加氧酶-1在复发性鼻息肉中的表达及意义, 昆明医科大学学报.
[8]	田锦涛. 脑缺血大鼠脑内AT1和AT2受体表达的免疫组化观察, 昆明医科大学学报.
[9]	胡继林. CSF-1及其受体与早期自然流产关系的研究, 昆明医科大学学报.
[10]	孟丽红. 首发为神经系统症状的低血糖反应临床分析, 昆明医科大学学报.
[11]	黄晓斌. 伽玛刀治疗吗啡依赖猴双侧伏隔核后多巴胺D3受体变化的研究, 昆明医科大学学报.
[12]	杨榆玲. 血管紧张素II 1型受体A1166C多态性在云南彝族人群中的分布, 昆明医科大学学报.
[13]	毕晓方. α1A受体阻滞剂在上尿路结石术后应用的临床研究, 昆明医科大学学报.
[14]	李劲涛. P38-一种信号分子在神经系统疾病中的作用, 昆明医科大学学报.
[15]	刘翱翔. 经颅磁刺激在神经系统疾病中的应用, 昆明医科大学学报.
[16]	李玉. 体外培养神经干细胞NGF、BDNF和NT-3及其受体trkA、trkB和trkC 的表达, 昆明医科大学学报.
[17]	. BDNF在树鼩中枢神经系统的表达, 昆明医科大学学报.
[18]	周磊. 高温对大鼠胚胎神经管发育畸形中BDNF及其受体mRNA表达变化的影响, 昆明医科大学学报.
[19]	杨晓文. 高迁移率族蛋白1及生长因子受体Ⅲ在乳腺癌组织中的表达及其临床意义, 昆明医科大学学报.
[20]	丁鹏. 新生大鼠海马神经干细胞表达趋化因子受体CCR2的体外研究, 昆明医科大学学报.

留言板

DRD1在神经系统疾病和功能中的研究进展

doi: 10.12259/j.issn.2095-610X.S20240501

作者简介: 李瑾瑜（2004～），女，云南昆明人，昆明医科大学在读本科生

通讯作者: 邹英鹰，E-mail：zouyingyingzyy@126.com

计量

出版历程

Research Progress of DRD1 in Neurological Disorders and Functions

计量

出版历程

目录

作者简介:
李瑾瑜（2004～），女，云南昆明人，昆明医科大学在读本科生

通讯作者:
邹英鹰，E-mail：zouyingyingzyy@126.com